Shortened Uncuffed Endotracheal Tube as a Nasopharyngeal Airway in Training in Fiberoptic Intubation

August 23, 2021 updated by: Ahmed Abodonya, Prince Sattam Bin Abdulaziz University

Using a Shortened Uncuffed Endotracheal Tube as a Nasopharyngeal Airway: a Useful Adjunct During Fiberoptic Intubation Training Among Anesthesia Residents

Background: Fiberoptic intubation is an effective technique for establishing airway access in patients with critical airways.

Objective: It was hypothesized that the learning of oral fiberoptic intubation by the anesthesia resident trainee is easier and safe using modified nasopharyngeal airway.

Methodology: This prospective randomized study was done on 62 adult patients with normal airway scheduled for elective oral fiberoptic intubation, their age 20 -60 years, 56 males and 6 females, American Society of Anesthesiologists I-III class. After institute ethical committee clearance and written informed consent, patients were randomly divided into two groups of 31 each; Group I: oral fiberoptic intubation was carried out using lingual traction. In group II, FOI was carried out using lingual traction plus a shortened uncuffed nasal endotracheal tube (modified nasopharyngeal airway). Time taken to successful tracheal intubation and other technical parameters were recorded. Heart rate, mean arterial blood pressure, oxygen saturation, end-tidal carbon dioxide tension, and any associated complications were also recorded.

Study Overview

Status

Completed

Conditions

Detailed Description

Patients with normal airway, 20 - 60 years, ASA grade I-III with mallampati class I or II were scheduled for elective oral FOI. Patients who refused to undergo the procedure, presence of an absolute contraindication to nasal intubation like head trauma, a nasal mass, and deviated nasal septum were excluded from the study.

Patients were randomly divided into two equal groups; Group I: FOI was carried out without NPA, and Group II: FOI was performed using NPA (NPA group). Lingual traction was used in both groups. Patients were optimized for surgery and fasting for 8 hours. While the patients in the preoperative holding area, they were premedicated with glycopyrrolate 0.2 mg intravenously 30 min prior to the procedure. At the same time, patients have been treated with xylometazoline 0.1% nasal drops in both nostrils followed by lignocaine jelly 2%.

All staff in the pre, intra, and postoperative area are licensed with ACLS according to the standard and guidelines of patient safety. The patient file and vital signs will be monitored during the stay in the holding area to discover any abnormalities. And each patient will sign a written consent form after explaining and informing about the procedure of the study. Vital signs (pulse, blood pressure, respiratory rate, and body temperature) and oxygen saturation will be checked before receiving any medication and frequently every 5 minutes till the end of the procedure to detect early concerns (hemodynamics instability, bleeding, neurocognitive dysfunction, and failed technique) The procedure was stopped if any patient feels abnormality or observed by a physician.

ENT consultant must be informed before the procedure to be around. Consultant Anesthesia will be closely included during the procedure for maintaining the accurate and optimum procedure.

In the operating room, patients were connected to standard monitors including pulse oximetry, ECG, non-invasive blood pressure, and temperature monitoring prior to administering premedication drugs. Then, 2 mg of midazolam and 50 μg fentanyl were injected intravenously 3 min prior to the procedure. In a group, II (NPA group), when the patient sedated with midazolam and fentanyl, a well-lubricated uncuffed tube (Portex®) 7.0 for male and 6.5 for female) was inserted nasally and advanced until the tip stands just above the opening of the larynx and then connected to a source of oxygen. After a period of 2-3 min of preoxygenation, the patient was anesthetized with total intravenous anesthesia (TIVA) using propofol and remifentanil infusion. The anesthesia resident trainee was asked to use a fiberoptic bronchoscope (Karl Storz® Intubation fiberscope 11301 BN1) to pass it through a cuffed endotracheal tube (ETT), visualize the vocal cords, pass through the glottic aperture and then pass the ETT over the fiberoptic bronchoscope. The correct ETT placement was confirmed by visualization of the carina and tracheal rings and bilateral equal air entry. The same scenario was done by the resident trainee in group I but without using the NPA.

The time of fiberscope insertion and intubation and the number of attempts were recorded. Hemodynamic and respiratory changes (HR, MAP, SpO2, and ETCo2) were recorded at 3 points; at the baseline before induction of anesthesia, during insertion of the scope (two minutes after induction of anesthesia), and after FOI (two minutes after securing ETT). Any adverse events were also recorded as sore throat, PONV, dental trauma,...etc. If necessary, facilitating techniques like jaw thrusts were used.

Study Type

Interventional

Enrollment (Actual)

62

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Riyadh
      • Al-kharj, Riyadh, Saudi Arabia, 11942
        • Prince Sattam bin Abdulaziz University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with normal airway,
  • 20-60 years,
  • ASA grade I - III with mallampati class I or II.

Exclusion Criteria:

  • Patients who refused to undergo the procedure,
  • Presence of an absolute contraindication to nasal intubation like head trauma, a nasal mass, and deviated nasal septum.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Group I
Fiberoptic intubation was carried out without nasopharyngeal airway
Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
Other Names:
  • Oral fiberoptic intubation
Other: Group II (NPA group)
Fiberoptic intubation was performed with a modified nasopharyngeal airway.
Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
Other Names:
  • Oral fiberoptic intubation plus modified nasopharyngeal airway

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxygen saturation
Time Frame: During procedure
It was regularly observed during procedure
During procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time taken to successful intubation
Time Frame: During procedure
It was recorded from starting to completion of fibroptic intubation
During procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

January 1, 2020

Study Completion (Actual)

March 1, 2021

Study Registration Dates

First Submitted

April 9, 2021

First Submitted That Met QC Criteria

April 17, 2021

First Posted (Actual)

April 21, 2021

Study Record Updates

Last Update Posted (Actual)

August 27, 2021

Last Update Submitted That Met QC Criteria

August 23, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • REC-HSD-67-2021

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgery

Clinical Trials on Group I

Subscribe